Get started

Nektar Therapeutics

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

NKTR chart

Key stats

Market capitalization
113.235MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.6268USD
Net income
−368.198MUSD
Revenue
92.055MUSD
Shares float
186.829M
Beta
1.99

About Nektar Therapeutics

Sector
Health Technology
CEO
Howard W. Robin
Headquarters
San Francisco
Website
nektar.com
Employees (FY)
216
Founded
1990
ISIN
US6402681083

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Ideas

NKTR High Tight Flag- Pre-Earnings High Flyer LONGNKTR is due for earnings on August 8th. The price from the opening bell on the 7th pump nearly 100% to over $1.00 and then faded by a couple of cents. The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity action into a high tight type bull falg which is often considered t
Long
3
monitor its daily price action to bottom fish itBased on 6 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $2.75 with a high forecast of $6.00 and a low forecast of $1.00. The average price target represents a 308.07% change from the last price of $0.67.
Long
Nektar Therapeutics (NASDAQ: $NKTR) Ready To Kick Cancer's Azz🦵Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3
Long
2
NEKTAR THERAPEUTICS AnnouncementHey my friends, NEKTAR THERAPEUTICS is in a compression zone, second attempt desperate for sellers with a large volume. Great possibility to break this area to look for the highest to breakout the balance area. Please LIKE & FOLLOW, thank you!
NKTR was a top gainer, rising +40.26%. Expect Uptrend reversalNektar Therapeutics (NKTR, $22.82) was one of top quarterly gainers, jumping +40.26% to $22.82 per share. My A.I.dvisor analyzed 169 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 156 of them (92.52%) charted an Uptrend while 13 of them (7.48%) trended
Long
1
Nektar is reaching fair valueNektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance). The 19% jump is making Nektar trading around its fair value. Like
1
Nektar Pharma - possible short squeezeThis is a speculative one as counter trend. Huge volume stepped in around $16 & $20 reuters data on November 28th shows short interest of 18% of the float, and 11 days to cover. The stock hi fresh highs since august and could pressure those short, extending the potential upside stop below 20 and
Long

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
No revenue here
This company hasn't generated any revenue in the last financial year
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.3Good
Learn more

See all brokers